2011’s Top Biopharma Dealmakers

By Amanda Micklus / Email the Author / IN VIVO January 2012, Vol. 30, No. 1
Deals In Depth / Word Count: 1024 / Article # 2012800004

Executive Summary

Big Pharma entered into fewer in-licensing deals in 2011 than it did in 2010. Top M&As focused on emerging markets. And neurology, cancer and metabolic disease were the most lucrative therapeutic areas in alliances.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 1024-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.
Subjects
Deals & Dealmaking Strategies
Industries
Biopharmaceuticals

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: 2011’s Top Biopharma Dealmakers

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to IN VIVO will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel